Search

Displaying results 2751 - 2760 of 5900 in total
  1. Drug

    Methoxyphenamine

    go.drugbank.com/drugs/DB13624
    Approved

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Ceftibuten

    go.drugbank.com/drugs/DB01415
    ApprovedInvestigational

    It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.

  3. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.

  4. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. … First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017.

  5. Drug

    Acamprosate

    go.drugbank.com/drugs/DB00659
    ApprovedInvestigational

    Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending. A...

  6. Drug

    Tetraethylammonium

    go.drugbank.com/drugs/DB08837
    Investigational

    Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. … Structurally, tetraethylammonium is positively charged due to its central quaternary ammonium.

  7. Drug

    Datopotamab deruxtecan

    go.drugbank.com/drugs/DB16410
    ApprovedInvestigational

    Datopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx. Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 20...

  8. Drug

    Idebenone

    go.drugbank.com/drugs/DB09081
    ApprovedInvestigational

    Due to its ability to reduce oxidative damage and improve ATP production, idebenone was originally investigated for its potential use in Alzheimer's Disease and other cognitivie disorders [A19769]. … More specifically, idebenone is thought to transfer electrons directly to complex III of the mitochondrial ETC, thereby circumventing complex I and restoring cellular energy (ATP) generation [L885].

  9. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.

  10. Drug

    Gabexate

    go.drugbank.com/drugs/DB12831
    Investigational

    It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]